PTX — Prescient Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$33.82m
- AU$26.90m
- AU$0.23m
Annual income statement for Prescient Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.066 | 0.044 | 0.459 | 0.688 | 0.226 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.19 | 5.21 | 7.46 | 8.9 | 7.54 |
| Operating Profit | -4.13 | -5.17 | -7 | -8.22 | -7.31 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.15 | -5.12 | -7 | -8.24 | -7.32 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.15 | -5.12 | -7 | -8.24 | -7.32 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.15 | -5.12 | -7 | -8.24 | -7.32 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.15 | -5.12 | -7 | -8.24 | -7.32 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.007 | -0.008 | -0.01 | -0.008 | -0.009 |